• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

Unsweetened coffee consumption is associated with reduced risk of mortality

byBryant LimandKiera Liblik
June 21, 2022
in Cardiology, Oncology, Public Health
Reading Time: 2 mins read
European data showed coffee consumption associated with lower mortality
Share on FacebookShare on Twitter

1. Moderate consumption of unsweetened and sugar-sweetened coffee was associated with reduced mortality from cancer and cardiovascular disease as compared to coffee abstinence.

2. Reduction in mortality for unsweetened coffee drinkers was sustained in subgroup analysis across lifestyle and sociodemographic factors.

Evidence Rating Level: 2 (Good)

Study Rundown: Previous observational studies have shown associations between coffee consumption and reduced risk of all-cause mortality. However, there is a paucity of data on the comparative mortality benefit of different types of coffee and the inclusion of sweeteners. The present prospective cohort study used data from the United Kingdom Biobank to evaluate the association between mortality and consumption of unsweetened, sugar-sweetened, and artificially sweetened coffee. Participants were followed for seven years after enrollment. Consumption of unsweetened coffee was associated with reduced risk of all-cause, cancer-specific, and cardiovascular-specific mortality after adjusting for lifestyle, sociodemographic, and clinical factors. Consistent associations between unsweetened coffee with reduced mortality were found for instant, ground, and decaffeinated coffee. Sugar-sweetened coffee was also significantly associated with reduced all-cause and cancer-specific mortality. The study was unable to find conclusive associations between artificially sweetened coffee drinkers and mortality due to the low sample size and statistical power of this group. There are several limitations to cohort studies that may impact the generalizability of these findings. These include self-selection bias of the participants, measurement error related to type and frequency of coffee consumption, and relatively short follow-up time.

Click to read the study in AIM.

Relevant Reading: Coffee consumption and all-cause and cause-specific mortality: a meta-analysis by potential modifiers

RELATED REPORTS

Borderline-low hemoglobin levels linked to increased mortality

Higher maternal body mass index is associated with increased risk of cardiovascular disease in offspring

Chronic exposure to particulate matter is associated with increased cardiovascular risk

In-Depth [prospective cohort]: The present study used data from the United Kingdom Biobank to evaluate the association between unsweetened, sugar-sweetened, and artificially sweetened coffee with mortality. Data on coffee consumption was obtained from a questionnaire that was administered to participants five times over one year about their dietary intake, including coffee, over the previous 24 hours. In the study cohort (n=171,616), 75.8% of participants reported drinking coffee at least one timepoint. Most coffee drinkers consumed unsweetened coffee (55%), followed by sugar (14%), and artificially (6%) sweetened coffee. The median follow-up time was seven years (interquartile range, 6.6 to 7.8). There was a significant U-shaped association between unsweetened coffee and sugar-sweetened coffee with all-cause mortality (p<0.001). The most beneficial effects are seen with moderate coffee consumption with increasingly harmful effects with excessive consumption. For unsweetened coffee, consumption of any amount was associated with a reduced risk of all-cause mortality after adjusting for lifestyle, sociodemographic, and clinical factors. Artificially sweetened coffee was not associated with improvements in risk for all-cause mortality. There was also a significant U-shaped association between unsweetened coffee and cancer and cardiovascular mortality (p<0.001). Moderate consumption of sugar and artificially sweetened coffee were weakly associated with lower cancer mortality. In summary, this study suggested potential health benefits associated with consuming unsweetened coffee compared to sugar or artificially sweetened coffee.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: caffienecancercardiovascular diseasecardiovascular preventioncoffeemortalityoncologypreventionpublic healthsweetener
Previous Post

ANNEXA-A and ANNEXA-R trials: Andaxanet Alfa for Reversal of Apixaban and Rivaroxaban [Classics Series]

Next Post

Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease

RelatedReports

Cardiology

Borderline-low hemoglobin levels linked to increased mortality

September 14, 2026
Behavioral dysregulation in infancy predicts later child mental health
Cardiology

Higher maternal body mass index is associated with increased risk of cardiovascular disease in offspring

September 12, 2026
Cardiology

Chronic exposure to particulate matter is associated with increased cardiovascular risk

September 10, 2026
Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening
Chronic Disease

Molecularly guided therapy may improve outcomes in patients with unfavourable cancer of unknown primary compared with standard chemotherapy

September 7, 2026
Next Post
Thalidomide may be effective in refractory pediatric Crohn’s disease

Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease

Estrogen withdrawal associated with perimenopausal depression

Accelerated approval drugs incur significant fee-for-service Medicare costs

Children’s hospital visits for suicide ideation and attempts are increasing

Islamic-based interventions may improve both depression and anxiety

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • First messenger RNA influenza vaccine outperforms standard-dose vaccination
  • Few interventions improve posthospitalization follow-up for alcohol use disorder
  • Borderline-low hemoglobin levels linked to increased mortality
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.